IBDEI1DN ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22964,2)
 ;;=^5001350
 ;;^UTILITY(U,$J,358.3,22965,0)
 ;;=C79.52^^107^1077^31
 ;;^UTILITY(U,$J,358.3,22965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22965,1,3,0)
 ;;=3^Secondary Malig Neop  Bone Marrow
 ;;^UTILITY(U,$J,358.3,22965,1,4,0)
 ;;=4^C79.52
 ;;^UTILITY(U,$J,358.3,22965,2)
 ;;=^5001351
 ;;^UTILITY(U,$J,358.3,22966,0)
 ;;=C92.00^^107^1077^25
 ;;^UTILITY(U,$J,358.3,22966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22966,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,22966,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,22966,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,22967,0)
 ;;=C92.40^^107^1077^30
 ;;^UTILITY(U,$J,358.3,22967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22967,1,3,0)
 ;;=3^Promyelocytic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,22967,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,22967,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,22968,0)
 ;;=C92.50^^107^1077^27
 ;;^UTILITY(U,$J,358.3,22968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22968,1,3,0)
 ;;=3^Myelomonocytic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,22968,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,22968,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,22969,0)
 ;;=C78.7^^107^1077^36
 ;;^UTILITY(U,$J,358.3,22969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22969,1,3,0)
 ;;=3^Secondary Malig Neop Liver & Intrahepatic Bile Duct
 ;;^UTILITY(U,$J,358.3,22969,1,4,0)
 ;;=4^C78.7
 ;;^UTILITY(U,$J,358.3,22969,2)
 ;;=^5001339
 ;;^UTILITY(U,$J,358.3,22970,0)
 ;;=C91.10^^107^1077^4
 ;;^UTILITY(U,$J,358.3,22970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22970,1,3,0)
 ;;=3^Lymphocytic Leukemia B-Cell Type,Chronic,Not in Remission
 ;;^UTILITY(U,$J,358.3,22970,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,22970,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,22971,0)
 ;;=D46.9^^107^1077^26
 ;;^UTILITY(U,$J,358.3,22971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22971,1,3,0)
 ;;=3^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,22971,1,4,0)
 ;;=4^D46.9
 ;;^UTILITY(U,$J,358.3,22971,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,22972,0)
 ;;=C79.31^^107^1077^33
 ;;^UTILITY(U,$J,358.3,22972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22972,1,3,0)
 ;;=3^Secondary Malig Neop Brain
 ;;^UTILITY(U,$J,358.3,22972,1,4,0)
 ;;=4^C79.31
 ;;^UTILITY(U,$J,358.3,22972,2)
 ;;=^5001347
 ;;^UTILITY(U,$J,358.3,22973,0)
 ;;=C79.32^^107^1077^34
 ;;^UTILITY(U,$J,358.3,22973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22973,1,3,0)
 ;;=3^Secondary Malig Neop Cerebral Meninges
 ;;^UTILITY(U,$J,358.3,22973,1,4,0)
 ;;=4^C79.32
 ;;^UTILITY(U,$J,358.3,22973,2)
 ;;=^5001348
 ;;^UTILITY(U,$J,358.3,22974,0)
 ;;=G89.3^^107^1077^28
 ;;^UTILITY(U,$J,358.3,22974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22974,1,3,0)
 ;;=3^Neoplasm Related Pain
 ;;^UTILITY(U,$J,358.3,22974,1,4,0)
 ;;=4^G89.3
 ;;^UTILITY(U,$J,358.3,22974,2)
 ;;=^5004159
 ;;^UTILITY(U,$J,358.3,22975,0)
 ;;=C79.82^^107^1077^35
 ;;^UTILITY(U,$J,358.3,22975,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22975,1,3,0)
 ;;=3^Secondary Malig Neop Genital Organs
 ;;^UTILITY(U,$J,358.3,22975,1,4,0)
 ;;=4^C79.82
 ;;^UTILITY(U,$J,358.3,22975,2)
 ;;=^267339
 ;;^UTILITY(U,$J,358.3,22976,0)
 ;;=I50.9^^107^1078^7
 ;;^UTILITY(U,$J,358.3,22976,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22976,1,3,0)
 ;;=3^Heart Failure,Unspec
 ;;^UTILITY(U,$J,358.3,22976,1,4,0)
 ;;=4^I50.9
 ;;^UTILITY(U,$J,358.3,22976,2)
 ;;=^5007251
 ;;^UTILITY(U,$J,358.3,22977,0)
 ;;=I73.9^^107^1078^13
 ;;^UTILITY(U,$J,358.3,22977,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22977,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
